Astellas v. Lupin: Consent Judgment Upholds Mirabegron Patent Rights in Landmark Pharma Case
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | Astellas Pharma, Inc. c. Lupin Limited |
| Numéro de dossier | 1:23-cv-00819 (D. Del.) |
| Tribunal | Tribunal fédéral de première instance pour le district du Delaware |
| Durée | July 28, 2023 – Feb 19, 2026 2 years 6 months |
| Résultat | Plaintiff Win — Permanent Injunction |
| Brevets en cause | |
| Produits incriminés | Lupin’s Mirabegron extended-release tablets (25 mg and 50 mg) |
Aperçu du dossier
Les parties
⚖️ Demandeur
Global biopharmaceutical company and originator of Myrbetriq® (mirabegron), a blockbuster treatment for overactive bladder approved by the FDA. Astellas holds an extensive patent portfolio protecting the drug’s active compound, extended-release formulation, and manufacturing processes.
🛡️ Défendeur
Major Indian generic pharmaceutical manufacturer with significant U.S. market operations. Lupin filed an Abbreviated New Drug Application (ANDA No. 209488) seeking to market generic Mirabegron extended-release tablets in 25 mg and 50 mg dosages — directly challenging Astellas’s market exclusivity.
Les brevets en cause
This landmark case involved four U.S. patents forming the core of this dispute. The infringement action arose under the Hatch-Waxman Act framework, triggered by Lupin’s ANDA filing with a Paragraph IV certification.
- • US11707451B2 — Mirabegron extended-release formulation (application US17/114890)
- • US ‘780 Patent — Related ER formulation technology
- • US ‘409 Patent — Related ER formulation technology
- • US ‘189 Patent — Related ER formulation technology
Vous développez une formulation pharmaceutique similaire ?
Check if your generic drug might infringe these or related patents before launch.
Le verdict et l'analyse juridique
Résultat
The court entered a consent judgment and final order on February 19, 2026. Based on Lupin’s admissions, all four asserted patents (‘780, ‘451, ‘409, and ‘189) were found **valid and enforceable**, and at least one claim of each patent was found **infringed** by the Lupin ANDA products. Lupin (including successors and assigns) is **permanently enjoined** from making, using, selling, offering to sell, importing, or distributing the ANDA products in the United States through the expiration of all four patents, including any patent term extensions, adjustments, pediatric exclusivity periods, or other regulatory exclusivities.
No specific monetary damages were awarded. The complaints across all four coordinated actions were dismissed **without prejudice and without costs** to either party.
Chronologie du litige et historique de la procédure
- July 28, 2023: Complaint filed in the U.S. District Court for the District of Delaware (Case No. 1:23-cv-00819).
- This action was part of a broader, coordinated litigation campaign by Astellas involving related civil actions — including Case Nos. 20-1589, 24-940, and 24-1069 — all before the same court.
- February 19, 2026: Consent judgment entered, closing the case after approximately 937 days of litigation. This duration is consistent with typical Hatch-Waxman district court timelines.
Signification juridique
This case reinforces a critical pattern in Hatch-Waxman litigation: **multi-patent assertion strategies materially increase settlement pressure on ANDA filers.** When a branded company constructs a patent estate with overlapping formulation, composition, and method claims — as Astellas has done with Mirabegron — generic challengers face the compounded risk of losing on any single patent, triggering injunctive relief regardless of success on others.
The consent judgment’s explicit extension of the injunction through **all regulatory exclusivities** — including pediatric exclusivity — is a drafting detail attorneys should note. This comprehensive scope prevents any exclusivity-gap strategy by the generic filer.
Analyse de la liberté d'exploitation (FTO)
This case highlights critical IP risks in pharmaceutical extended-release formulations. Choose your next step:
📋 Comprendre l'impact de cette affaire
Découvrez les risques et les implications spécifiques liés à ce litige.
- Voir les 4 brevets dans ce domaine technologique
- See which companies are most active in OAB drug patents
- Understand claim scope of ER patents
🔍 Vérifier les risques liés à mon produit
Run a comprehensive FTO analysis for your own generic formulation or compound.
- Saisissez la description de votre produit ou ses caractéristiques techniques.
- L'IA identifie les brevets susceptibles de constituer un obstacle
- Obtenir un rapport d'évaluation des risques exploitable
Zone à haut risque
Mirabegron extended-release formulations
4 Patents
In this formulation family
Options de contournement
Disponible pour certaines réclamations
✅ Points clés à retenir
Multi-patent Hatch-Waxman assertion strategies create compounding settlement pressure on ANDA challengers.
Rechercher la jurisprudence connexe →Consent judgments should expressly extend injunctions through all patent term extensions, adjustments, and regulatory exclusivities.
Explorer les précédents →Foire aux questions
The case involved four patents — referred to as the ‘780, ‘451, ‘409, and ‘189 patents — including U.S. Patent No. US11707451B2, covering Mirabegron extended-release tablet formulations in 25 mg and 50 mg dosages.
Lupin admitted that all four asserted patents are valid and enforceable and that at least one claim of each patent is infringed by its ANDA products, resulting in a permanent injunction through patent expiration.
The consolidated consent judgments across multiple Lupin-related actions effectively delay generic Mirabegron entry until expiration of the full patent family, including all patent term extensions and regulatory exclusivities.
Prêt à renforcer votre stratégie en matière de propriété intellectuelle pharmaceutique ?
Rejoignez plus de 18 000 professionnels de la propriété intellectuelle qui utilisent PatSnap Eureka pour effectuer des recherches d'antériorité, rédiger des brevets et analyser le paysage concurrentiel avec une précision optimisée par l'IA.
Références
- United States District Court for the District of Delaware — Civil Action No. 1:23-cv-00819 (PACER)
- U.S. Patent and Trademark Office — U.S. Patent No. US11707451B2
- Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act)
- FDA — ANDA Resources
- PatSnap — Pharmaceutical IP Solutions
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.